Companion Animal Vaccines Market record sales worth U.S. $ 4.9 Billion by the end of 2028.

FDA approvals for novel and innovative companion animal vaccines continue to present potential growth opportunities to R&D of companion animal vaccines. For instance, Zoetis received regulatory approval for ProHeart, used for prevention of heartworm diseases caused by Dirofilaria immitis in dogs.

Request Sample Copy of Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-1427

Key Takeaways – Companion Animal Vaccines Market Study

• Attenuated live vaccines currently account for more than a third of total market value, and will continue to witness a healthy CAGR through 2029. This demand growth is attributed to their improved effectivity and enhanced long-term preventive action.
• North America is witnessing lucrative market growth compared to other regions attributed to increase in the adoption rate of companion animals, increase in veterinary healthcare expenditure, and increasing awareness about pet health.
• Veterinary animal hospitals and clinics offering better service support for animal care are expected to  have  significant market share during the forecast period
• As large number of people are in close contact with canine animals as a preference for companion animal, demand will be prominent among canine species.

Increasing R&D Investments to Widen Market Growth Prospects

Elanco, Ceva Sante Animale, Boehringer Ingelheim are among the leading market players in the companion animal vaccines market. These manufacturers continue to dominate the market landscape of companion animal vaccines by investing heavily in R&D activities to develop and launch therapeutic vaccines for prevention and treatment of various animal diseases. Surge in investment for R&D of vaccines, which inhibit the growth of antibiotic-resistant organisms boosts the animal vaccines market growth.

For instance, in August 2018, Elanco invested two-thirds of the budget for food‐animal unit to develop vaccines and reduce the use of antibiotics. Moreover, rise in demand for animal vaccines led to the development of multiple new vaccines. For instance, Cevac IBron a new vaccine was launched by Ceva in February 2017 for prevention against infectious bronchitis virus (IBV) in animals.

Know More About Companion Animal Vaccines Market Report

Future Market Insight brings the comprehensive research report on forecast revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2014 to 2029. The global companion animal vaccines is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader. The study provides compelling insights of the companion animal vaccines market on basis of product type (attenuated live vaccines, conjugated vaccines, inactivated vaccines, subunit vaccines, toxoid vaccines, DNA vaccines, recombinant vaccines), species type (canine, avian, feline) and distribution channel (companion animal hospitals, companion animal hospitals, companion animal research institutes) across seven major regions.

Ask from the Market Research Expert @ https://www.futuremarketinsights.com/ask-question/rep-gb-1427

Segmented 

Product

• Attenuated Live Vaccines
• Conjugate Vaccines
• Inactivated Vaccines
• Subunit Vaccines
• Toxoid Vaccines
• DNA Vaccines
• Recombinant Vaccines

Species

• Canine
• Avian
• Feline

Distribution Channel

• Veterinary Clinics
• Veterinary  Hospitals
• Veterinary Research Institutes
• Retail Pharmacies

Region

• North America
• Latin America
• Western Europe
• Eastern Europe
• Asia Pacific excluding Japan
• Japan
• Middle East & Africa